Search the Newsreel

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Pharvaris (NASDAQ:PHVS) Given New $75.00 Price Target at Citizens Jmp

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - What's Next?

Pharvaris (NASDAQ:PHVS) recently hit a new 52-week high of $36.65, with a current market capitalization of $2.38 billion, despite missing its latest quarterly earnings estimate. Analyst sentiment is generally positive with a "Moderate Buy" consensus and an average price target of $50.08, though some …

Citizens raises Pharvaris stock price target to $75 on trial progress

Citizens has increased its price target for Pharvaris B.V. to $75.00 from $74.00, maintaining a Market Outperform rating, due to ongoing trial progress. The company's stock has surged 70% in the past year, and key Phase 3 CHAPTER-3 data is expected this quarter. Pharvaris …

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What Happened

Pharvaris (NASDAQ:PHVS) experienced unusually high trading volume, with 487,339 shares traded, marking a 60% increase from the previous session. The stock closed at $34.48, and analysts maintain a "Moderate Buy" rating with an average price target of $50.08 despite the company missing quarterly EPS …

Pharvaris (NASDAQ:PHVS) Releases Earnings Results, Misses Expectations By $0.05 EPS

(PHVS) as a Liquidity Pulse for Institutional Tactics

This article provides a detailed AI-driven analysis of Pharvaris N.v. (NASDAQ: PHVS), highlighting a strong near-term sentiment moving towards a long-term positive bias. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific entry, target, and stop-loss …

Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share

Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date

Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position

Pharvaris reported its Q2 2026 financial results, with cash and cash equivalents of €318 million, providing a financial runway into 2028. The company is advancing deucrictibant for bradykinin-mediated angioedema, with topline data from the pivotal Phase 3 CHAPTER-3 study expected in Q3 2026, and …

Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly reduced its stake in Pharvaris N.V. by 44.7% in Q1 2026, selling 35,695 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $50.08, while company insiders have recently sold a substantial number …

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Analysts have given Pharvaris N.V. (NASDAQ:PHVS) a "Moderate Buy" consensus recommendation, with an average 12-month price target of $50.08, exceeding its current share price of $34.91. While insider selling has occurred recently, the clinical-stage biotech company, focused on hereditary angioedema with its lead candidate …

Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage?

Pharvaris (PHVS) recently published a study detailing the disease burden of acquired C1 inhibitor deficiency (AAE-C1INH) and validating patient-reported outcome tools. This research directly influenced endpoint selection for their Phase 3 CREAATE trial, potentially strengthening future clinical benefit assessments. While this offers a supporting …

Claude AI’s Newest Stock Picks Are Also Hedge Fund Favorites: One Breakout Biotech, One AI Chip Bet

Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a live portfolio. Claude AI recently added two names that couldn't …

Pharvaris publishes study on rare angioedema condition

Pharvaris (NASDAQ:PHVS) announced the publication of a qualitative study on acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) in Frontiers in Immunology. This study, the first in-depth assessment of the rare condition, highlighted frequent misdiagnoses, severe attacks, and significant life disruptions for patients who …

Pharvaris (PHVS) Projected to Release Quarterly Earnings on Tuesday

ETFs Investing in Pharvaris N.V. Stocks

This article lists various ETFs that include Pharvaris N.V. (A2QNWS) stocks in their holdings. It provides detailed information for each ETF, such as market value, weight of Pharvaris N.V. stock, issuer, management style, expense ratio, AUM, price, and performance metrics like 3-year NAV total …

(PHVS) Risk Channels and Responsive Allocation

Pharvaris N.v. (NASDAQ: PHVS) is showing weak near and mid-term sentiment, despite a positive long-term outlook, with resistance currently being tested. An exceptional 30.0:1 risk-reward short setup is identified, targeting 8.2% downside against 0.3% risk. The article outlines institutional trading strategies including position trading, …

Pharvaris N.V. (PHVS) investor LSP V trims stake to 4.9% of shares

LSP V Cooperatieve U.A. and LSP V Management B.V. have reported an amended beneficial ownership stake of 4.9% in Pharvaris N.V. (PHVS), based on a Schedule 13G/A filing. This percentage represents 3,424,609 ordinary shares out of 69,666,453 shares outstanding following an underwritten offering in …

Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pharvaris NV (PHVS), listing major shareholders like General Atlantic LLC and Fidelity Management & Research Company LLC. It breaks down shareholder types, including private equity and hedge funds, and provides a quarterly overview of institutional shareholdings and …

Pharvaris NV (PHVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for Pharvaris NV (PHVS), indicating that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Despite providing a stock overview with current trading figures and market cap, specific financial …

Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pharvaris NV (PHVS) regarding its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years and contains no data on dividend dates. The article includes current stock trading …

PHVS|Pharvaris NV|Price:34.170|Chg%:+0.910

This article provides an overview of Pharvaris NV (PHVS) stock performance, showing a closing price of $34.170 with a 2.74% increase. It details how TradingKey generates its comprehensive stock scores, including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk management, although …

Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pharvaris NV (PHVS), detailing its support, resistance levels, and performance based on various indicators and moving averages. It offers a summary of several technical indicators like MACD, RSI, and StochRSI, along with their current values and directions, …

Pharvaris NV (PHVS) Institutional Confidence

This article provides an overview of institutional shareholding in Pharvaris NV (PHVS), detailing the top institutional investors and their respective shareholdings. Key investors include General Atlantic LLC, Fidelity Management & Research Company LLC, and Foresite Capital Management, LLC. The report also highlights changes in …

Pharvaris NV (PHVS) Cash Flow

This article provides a detailed cash flow statement for Pharvaris NV (PHVS), presenting both quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income from continuing operations, capital expenditures, and free cash flow over several …

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

Key Points Schikan sold 37,600 shares over June 29, 2026 and June 30, 2026, generating ~ $1.33 million in gross proceeds based on a weighted average price of around $35.41 per share. This transaction represented 10.66% of his direct holdings, reducing his directly held …

Pharvaris publishes review on bradykinin B2 receptor research

Pharvaris (NASDAQ:PHVS) has published a review article in Clinical Reviews in Allergy & Immunology discussing the biology of bradykinin and the bradykinin B2 receptor. The article examines the scientific and clinical research supporting bradykinin B2 receptor antagonism as a therapeutic approach for bradykinin-mediated diseases, …

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases ZUG, Switzerland, July 22, 2026 (GLOBE …

(PHVS) Movement as an Input in Quant Signal Sets

This article analyzes Pharvaris N.v. (NASDAQ: PHVS) using AI models, identifying a weak near-term sentiment despite long-term strength. It outlines specific trading strategies including position, momentum breakout, and risk hedging, complete with entry points, targets, and stop losses. The analysis also provides multi-timeframe signal …

Pharvaris N.V. (PHVS) CEO sells 2,292 shares in Rule 10b5-1 stock plan

Pharvaris N.V.'s CEO, Berndt Modig, sold 2,292 shares of common stock on July 13, 2026, for a weighted average price of $34.9714 per share through a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Modig directly holds 132,917 shares and indirectly holds 950,000 shares …